Curis ca-4948 nhl ash presentation 2020
WebCA-4948 in patients expressing IRAK4-L •Capitalize on unique clinical experience with VISTA by in-licensing the leading monoclonal antibody program (CI-8993) and initiating a Ph1 study in solid tumors 2024 2024 2024 Initial Clinical Data Report preliminary efficacy data for CA-4948 Ph1 study in NHL Evaluate new published research in WebCA-4948 is the first clinical candidate targeting IRAK4 to be evaluated in cancer patients. Here we present Phase I results of CA-4948 in patients with relapsed/refractory hematologic malignancies. Method CA-4948-101 is a phase I trial dose escalation trial with a …
Curis ca-4948 nhl ash presentation 2020
Did you know?
WebDec 7, 2024 · Curis slumps ( CRIS -25.0%) as investors seem to be disappointed on updated data from its ongoing Phase 1 study evaluating of CA-4948, an IRAK4 kinase inhibitor, for the treatment of relapsed... WebNov 10, 2024 · Curis expects to initiate a Phase 1 study evaluating CA-4948 in combination with ibrutinib, a BTK inhibitor. In preclinical models, CA-4948 has demonstrated anti-cancer activity that is highly synergistic with BTK inhibition. The Company will present a Trial in Progress poster at ASH.
WebNov 6, 2024 · As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA ... WebNov 10, 2024 · Curis management will host a conference call today, November 10, 2024, at 4:30 p.m. ET, to discuss these financial results, as well as provide a corporate update. To access the live conference...
WebNov 4, 2024 · Details of the presentations are as follows: Oral Presentation: Title: Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or... WebDec 7, 2024 · Curis Announces Updated Preliminary Data from Ongoing Phase 1 Study of CA-4948 Showing Durable and Dose-Dependent Reductions in Tumor Burden in Patients with Relapsed or Refractory...
WebCA-4948 is a novel oral IRAK4 inhibitor of the TLR/myddosome Pathway • Well absorbed; pharmacokinetics are predictable and support BID dosing • Well tolerated; safety profile allows long-term treatment and combination with other active drugs against NHL • Pharmacodynamic analyses demonstrate NFκB inhibition and reduction of cytokine release
WebMay 13, 2024 · Curis, whose market cap now sits at nearly $1.5bn, has a lot riding on CA-4948. Its next most advanced asset is the anti-Vista monoclonal antibody CI-8993, on which phase 1 data is due in the second half of the year. Two further clinical-stage assets are on ice after earlier disappointments. so if you wake up with the sunrise lyricsWebJun 4, 2024 · Curis is also evaluating CA-4948 in a Phase 1/2 trial in patients with acute myeloid leukemia and myelodysplastic syndromes, for which it has received Orphan Drug Designation from the U.S. Food ... so if you love meWebMar 16, 2024 · As of December 31, 2024, Curis' cash, cash equivalents and investments totaled $183.1 million, which includes net proceeds of $159.1 million from our follow-on public offering in December... so if you really love me let it showWebMar 16, 2024 · In December 2024, Curis announced positive preliminary data from its ongoing Phase 1 study of CA-4948 monotherapy in patients with R/R AML and high-risk MDS, including marrow blast reductions observed in all evaluable patients and 2 of 6 evaluable patients experiencing a marrow complete response. so if you really love me say yesWebMay 12, 2024 · First Quarter 2024 Financial Results. For the first quarter of 2024, Curis reported a net loss of $9.9 million or $0.11 per share on both a basic and diluted basis, as compared to a net loss of $9 ... so i gave it to the catWebMay 12, 2024 · Curis Reports Updated Data in Two Abstracts for CA-4948 Accepted for Presentation at the European Hematology Association 2024 Virtual Congress /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS),... so i get on the road and ride to youWebCuris CA-4948 NHL ASH Presentation 2024 - Curis, Inc About Company Overview Management Board of Directors History Collaborations Partner Collaborations Scientific & Research Collaborations Patients Patients Overview About Clinical Studies Current Studies Compassionate Use Policy Pipeline Pipeline Overview Emavusertib (CA-4948) CI-8993 … sls mercedes amg